Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

LYMPHOMA

Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

Leukemia volume 39, pages 243–247 (2025)Cite this article

Subjects

A Correction to this article was published on 10 November 2025

This article has been updated

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Whole-genome CRISPR library screen identifies endogenous MCC inhibitor MAD2L1BP and ANAPC15 as sensitizing genes to BV in CD30-positive PTCL cells.
Fig. 2: APC/C inhibitor proTAME synergizes with BV.

Change history

  • 05 November 2025

    The original online version of this article was revised: The BV concentration units were incorrectly labeled as pM due to an error in molar conversion. The correct unit used in all experiments was nM. This labeling error appears in the following sections: Figures: 1D, 2A, 2B, 2C, 2F Supplementary Figures: 1A, 1D, 3B, 4G, 5B, 5C Supplementary Materials and Methods: Genome-wide CRISPR library screen The original article has been corrected.

  • 10 November 2025

    A Correction to this paper has been published: https://doi.org/10.1038/s41375-025-02811-3

References

  1. Horwitz S, O’Connor OA, Pro B, Trumper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288–98.

    Article  CAS  PubMed  Google Scholar 

  2. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123:3095–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–6.

    Article  CAS  PubMed  Google Scholar 

  4. Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14:1376–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, et al. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. Blood. 2022;140:1951–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, et al. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. Blood. 2022;139:1541–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Nakagawa M, Shaffer AL 3rd, Ceribelli M, Zhang M, Wright G, Huang DW, et al. Targeting the HTLV-I-regulated BATF3/IRF4 transcriptional network in adult T cell leukemia/lymphoma. Cancer Cell. 2018;34:286–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Fauster A, Rebsamen M, Willmann KL, Cesar-Razquin A, Girardi E, Bigenzahn JW, et al. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death Differ. 2019;26:1138–55.

    Article  CAS  PubMed  Google Scholar 

  9. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10:457–70.

    Article  CAS  PubMed  Google Scholar 

  10. Nawrocki JF, Kirsten ES, Fisher RI. Biochemical and structural properties of a Hodgkin’s disease-related membrane protein. J Immunol. 1988;141:672–80.

    Article  CAS  PubMed  Google Scholar 

  11. McAinsh AD, Kops G. Principles and dynamics of spindle assembly checkpoint signalling. Nat Rev Mol Cell Biol. 2023;24:543–59.

    Article  CAS  PubMed  Google Scholar 

  12. Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh DC, et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 2010;18:382–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lok TM, Wang Y, Xu WK, Xie S, Ma HT, Poon RYC. Mitotic slippage is determined by p31(comet) and the weakening of the spindle-assembly checkpoint. Oncogene. 2020;39:2819–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Mansfeld J, Collin P, Collins MO, Choudhary JS, Pines J. APC15 drives the turnover of MCC-CDC20 to make the spindle assembly checkpoint responsive to kinetochore attachment. Nat Cell Biol. 2011;13:1234–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ma HT, Chan YY, Chen X, On KF, Poon RY. Depletion of p31comet protein promotes sensitivity to antimitotic drugs. J Biol Chem. 2012;287:21561–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank K Suganuma, ME Kadin, and TA Waldmann for cell lines and C Yokoyama for technical assistance.

Funding

This research was supported by JSPS KAKENHI Grant Number JP21H02775, research funding from Takeda Pharmaceutical Company Limited. and research grants from The Princess Takamatsu Cancer Research Fund and Takeda Science Foundation for MN, by JSPS KAKENHI Grant Number 23K15314 for TI and by NIH R01 CA259188, CA251674, American Cancer Society RSG-23-722314, and Scholar Award from the Leukemia & Lymphoma Society for YY.

Author information

Authors and Affiliations

  1. Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan

    Keito Suto, Keito Yokoyama, Masahiro Chiba, Takashi Ishio, Hideki Goto, Tomoyuki Endo, Takanori Teshima & Masao Nakagawa

  2. Institute for Animal Experimentation, Hokkaido University Faculty of Medicine, Sapporo, Japan

    Norio Takei

  3. Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan

    Michiyuki Maeda

  4. Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA

    Yibin Yang

Authors
  1. Keito Suto
    View author publications

    Search author on:PubMed Google Scholar

  2. Norio Takei
    View author publications

    Search author on:PubMed Google Scholar

  3. Keito Yokoyama
    View author publications

    Search author on:PubMed Google Scholar

  4. Masahiro Chiba
    View author publications

    Search author on:PubMed Google Scholar

  5. Takashi Ishio
    View author publications

    Search author on:PubMed Google Scholar

  6. Michiyuki Maeda
    View author publications

    Search author on:PubMed Google Scholar

  7. Hideki Goto
    View author publications

    Search author on:PubMed Google Scholar

  8. Tomoyuki Endo
    View author publications

    Search author on:PubMed Google Scholar

  9. Takanori Teshima
    View author publications

    Search author on:PubMed Google Scholar

  10. Yibin Yang
    View author publications

    Search author on:PubMed Google Scholar

  11. Masao Nakagawa
    View author publications

    Search author on:PubMed Google Scholar

Contributions

KS designed, performed the experiments, analyzed the data, and wrote the manuscript. NT designed, performed the experiments, and analyzed the data. KY, MC, and TI performed the experiments. TE, HG, and TT analyzed the data. MM contributed vital resources. YY assisted and supported the research. MN designed, and performed experiments, analyzed data, wrote the manuscript, and supervised the research.

Corresponding author

Correspondence to Masao Nakagawa.

Ethics declarations

Competing interests

MN received research funding from Takeda Pharmaceutical Company Limited. The other authors declare no competing financial interests related to this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: The BV concentration units were incorrectly labeled as pM due to an error in molar conversion. The correct unit used in all experiments was nM. This labeling error appears in the following sections: Figures: 1D, 2A, 2B, 2C, 2F Supplementary Figures: 1A, 1D, 3B, 4G, 5B, 5C Supplementary Materials and Methods: Genome-wide CRISPR library screen The original article has been corrected.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suto, K., Takei, N., Yokoyama, K. et al. Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma. Leukemia 39, 243–247 (2025). https://doi.org/10.1038/s41375-024-02441-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41375-024-02441-1

Search

Advanced search

Quick links